COVID-19 News: Harvard Randomized Trial Surprisingly Finds That Untreated COVID-19 Individuals Fair Better Than Those Treated With Paxlovid!
: A new study conducted by researchers from Brigham and Women's Hospital, Harvard Medical School,Massachusetts-USA and Harvard T.H. Chan School of Public Health-Massachusetts-USA involving a randomized clinical trial has surprisingly found that untreated COVID-19 infected individuals tend to fair better than those treated with Paxlovid (nirmatrelvir–ritonavir) in terms of symptoms and viral rebound!
To date, though symptom and viral rebound have been reported after nirmatrelvir–ritonavir treatment, the trajectories of symptoms and viral load during the natural course of COVID-19 have not been well described.
The Harvard study team aimed in their study to characterize symptom and viral rebound in untreated outpatients with mild to moderate COVID-19.
The study involved a Retrospective analysis of participants in a randomized, placebo-controlled trial held in a multicenter setting.
The clinical trial involved a total of 563 participants receiving placebo in the ACTIV-2/A5401 (Adaptive Platform Treatment Trial for Outpatients With COVID-19) platform trial.
Study participants recorded the severity of 13 symptoms daily between days 0 and 28. Nasal swabs were collected for SARS-CoV-2 RNA testing on days 0 to 14, 21, and 28. Symptom rebound was defined as a 4-point increase in total symptom score after improvement any time after study entry. Viral rebound was defined as an increase of at least 0.5 log10 RNA copies/mL from the immediately preceding time point to a viral load of 3.0 log10 copies/mL or higher. High-level viral rebound was defined as an increase of at least 0.5 log10 RNA copies/mL to a viral load of 5.0 log10 copies/mL or higher.
The study findings showed that symptom rebound was identified in 26% of participants at a median of 11 days after initial symptom onset. Viral rebound was detected in 31% and high-level viral rebound in 13% of participants. Most symptom and viral rebound events were transient, because 89% of symptom rebound and 95% of viral rebound events occurred at only a single time point before improving.
Importantly, the combination of symptom and high-level viral rebound was only observed in 3% of participants.
The study findings were published in the peer reviewed journal: Annals Of Internal Medicine.
Thailand Medical News in our previous COVID-19 News
coverages had already warned about the various ‘hopeless’ and in some cases toxic and mutagenic drugs being promoted by the greedy and corrupted American agencies like the U.S. FDA, U.S. NIH etc. To a large extent, it can be claimed that more people died from the effects of these drugs than the virus itself but we will never know the truth as proper autopsies were never done and most hospitalized SARS-CoV-2 infected individuals who died often had their death certificates attributing COVID-19 as the cause of death!
(Please use the search function on TMN site, there are more than 67 different articles on the ineffectiveness and toxicity of the various U.S. FDA approved drugs to treat COVID-19!)
This Harvard study showed that a combination of symptoms and viral rebound after untreated COVID-19 infection is rare, occurring in only 3% of study participants.
Paxlovid (Nirmatrelvir–ritonavir) is being promoted as a recommended treatment for outpatients with mild to moderate COVID-19 and risk factors for severe disease.
However, widespread use of Paxlovid has been accompanied by reports of worsening symptoms and virologic rebound after treatment completion.
Interestingly, virologic rebound has also been reported in individuals who did not receive Paxlovid therapy, but studies that can define the frequencies of symptom and viral rebound during the natural course of COVID-19 are lacking.
The study team conducted an analysis of 563 participants receiving placebo in the ACTIV-2/A5401 (Adaptive Platform Treatment Trial for Outpatients With COVID-19) platform trial.
The researchers found that a combination of symptom and high-level viral rebound occurred in only 3% of participants. Symptom rebound alone occurred in 26% of participants 11 days after initial symptom onset and viral rebound alone occurred in 31% of participants. High-level viral rebound was observed in 13% of participants.
The study team noted that both symptom and viral rebound were short, lasting only one day in most participants.
The study team stressed that these study findings highlight the importance of accounting for underlying rates of symptom relapse in the absence of antiviral therapy when evaluating the effects of antiviral treatments.
For the latest COVID-19 News
, keep on logging to Thailand Medical News.